At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

We believe Vertex is in strong financial health, given its robust cash flow generation and low debt. At the end of 2024, Vertex held about $11.2 billion in cash and equivalents.

CRISPR Therapeutics partnered with big biotech Vertex Pharmaceuticals ( VRTX 3.40%) on Casgevy. Although Vertex takes a ...

Vertex Pharmaceuticals is diversifying its already strong lineup of medicines. Axsome Therapeutics has multiple clinical and ...

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we ...

And that statement also applies to another new launch -- non-opioid painkiller Journavx. Vertex expects to transition ...

These drugs represent billion-dollar opportunities for Vertex, and Journavx is particularly interesting because it opens the door to an entirely new treatment area for the company. Journavx is a ...

Vertex remains focused on diversifying its product portfolio and recently launched two new approved therapies: Alyftrek and Journavx. Alyfrtek is an improvement to VRTX’s CF portfolio ...

Parnassus Growth Equity Fund (Investor Shares) returned -8.59% (net of fees) for the quarter, faring better than the Russell ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.